SPECT/CT Device for Theranostic Imaging Debuts at EANM Meeting
Designed for theranostic imaging applications, the AnyScan Trio SPECT/CT TheraMax scanner was recently unveiled at the annual meeting of the European Association of Nuclear Medicine (EANM).
Offering enhanced sensitivity and spatial resolution capability approaching that of positron emission tomography (PET), the AnyScan Trio SPECT/CT TheraMax system was introduced at the European Association of Nuclear Medicine (EANM) annual conference in Hamburg, Germany.
Designed with an emphasis on targeted radionuclide therapy applications, the AnyScan Trio SPECT/CT TheraMax platform includes detectors and collimators that enable the use of alpha- and beta-emitting radiopharmaceuticals as well as high-energy gamma photons such as lutetium-177 (177Lu) and actinium-225 (225Ac), according to Mediso, the manufacturer of the AnyScan Trio SPECT/CT TheraMax device.
Recently installed at the University Hospital Regensburg in Regensburg, Germany, the AnyScan Trio SPECT/CT TheraMax system was designed with an emphasis on targeted radionuclide therapy applications, according to Mediso, the manufacturer of the system. (Photo courtesy of Mediso.)
The company noted that other features and capabilities of the system include:
• surface detectors up to five times larger than those utilized in 12-detector cadmium zinc telluride (CZT) platforms;
• PET-like image quality with bolstered spatial resolution facilitated by the platform’s high-density sensor arrangement;
• whole-body SPECT/CT scans with up to 300 percent higher sensitivity in comparison to conventional dual-detector devices; and
• integrated computed tomography (CT) options for low-dose, ultra-low dose and “zero-dose” protocols with artificial intelligence (AI)-enabled SyCT (Synthetic CT).
"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT," said Istvan Bagaméry, the managing director of Mediso. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."
Recent Videos
Related Content
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025Article
In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
